Hematology & Thromboembolism – Full-Time Faculty
Information Box Group
Donald Arnold
MD, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
John G. Kelton Chair in Translational Research
Donald Arnold
MD, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
John G. Kelton Chair in Translational Research
Shannon Bates
MDCM, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Eli Lilly Canada/May Cohen Chair in Women's Health
Shannon Bates
MDCM, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Eli Lilly Canada/May Cohen Chair in Women's Health
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Jonathan Bramson
PhD
Vice-Dean, Research
Professor, Division of Hematology & Thromboembolism; John Bienenstock Chair in Molecular Medicine
Research Interests: Immunology, Oncology, Translational Research, Genetic Engineering, Immunoassays/Immune Monitoring, First-in-human clinical trials
Jonathan Bramson
PhD
Vice-Dean, Research
Professor, Division of Hematology & Thromboembolism; John Bienenstock Chair in Molecular Medicine
Mark Crowther
MD, MSc, FRCPC
Professor; Chair, Department of Medicine
Leo Pharma Chair in Thromboembolism Research; Clinical Epidemiology and Biostatistics, Pathology and Molecular Medicine associate member
Education and Professional Standing
MD, University of Western Ontario, 1990
FRCPC Internal Medicine, 1994
FRCPC Hematology, 1995
MSc Health Research Methodology, 1998
Fellow of the Royal Society of Canada (FRSC), 2017
Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter’s annual publication of The World’s Most Influential Scientific Minds).
[View Dr. Crowther’s citations on PubMed]
Research Interests: Exploring ways of improving the way that we use our current anticoagulant drugs, including exploring established and novel interventions to mitigate bleeding and anticoagulant drugs in high-risk patient populations; Developing systematic reviews of key questions in hematology and thrombosis and basing guidelines on those reviews.
Mark Crowther
MD, MSc, FRCPC
Professor; Chair, Department of Medicine
Leo Pharma Chair in Thromboembolism Research; Clinical Epidemiology and Biostatistics, Pathology and Molecular Medicine associate member
John Eikelboom
MBBS, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Research; Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research
Dr John Eikelboom is an associate professor in the Department of Medicine at McMaster University in Hamilton, Ontario . After earning his MBBS degree at the University of Western Australia Medical School, Australia, he completed training in Internal Medicine and Haematology at Royal Perth Hospital, Australia and trained in Epidemiology and Thrombosis Medicine at McMaster University . He holds a Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research. Dr. Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding. He has published more than 150 peer-reviewed papers. He is a member of the Editorial Board for Stroke and on the Advisory Board for the Journal of Thrombosis and Haemostasis.
Research Interests: Mechanisms and genetic determinants of antiplatelet drug resistance and improving its diagnosis and treatment.
John Eikelboom
MBBS, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Research; Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Jeffrey Ginsberg
MD, FRCPC
Professor Emeritus
Jeffrey Ginsberg
MD, FRCPC
Professor Emeritus
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Patricia Liaw
BSc, MSc, PhD
Professor, Division of Hematology & Thromboembolism
Jack Hirsh-Clive Kearon Chair in Thrombosis
Patricia Liaw
BSc, MSc, PhD
Professor, Division of Hematology & Thromboembolism
Jack Hirsh-Clive Kearon Chair in Thrombosis
Brian Lichty
PhD
Associate Professor
Research Interests: Host-virus interactions and viral therapeutics for cancer
Davide Matino
MD, MSc
Assistant Professor, Division of Hematology & Thromboembolism
Bayer Chair for Clinical Epidemiology Research in Bleeding Disorders
Davide Matino
MD, MSc
Assistant Professor, Division of Hematology & Thromboembolism
Bayer Chair for Clinical Epidemiology Research in Bleeding Disorders
Siraj Mithoowani
MD, FRCPC
Assistant Professor
Member, McMaster Education Research, Innovation & Theory (MERIT) Program
Siraj Mithoowani
MD, FRCPC
Assistant Professor
Member, McMaster Education Research, Innovation & Theory (MERIT) Program
Ishac Nazy
PhD
Associate Professor
Research interests are in the specific interactions between antibodies and their target antigens on platelets, leading to thrombocytopenia and/or thrombosis. Heparin induced thrombocytopenia and Immune thrombocytopenia (ITP) are great models for identifying key factors involved in the pathogenesis of the immune responses leading to low platelet counts. Our research focuses on the cellular and humoral immunity and the downstream effects on platelet physiology. We use our research to identify the pathology from patient samples and create in-vitro models that could explain our findings and further our understanding of the issues at hand.
Anthony Rullo
PhD
Associate Professor
Associate Member, Department of Biochemistry and Biomedical Sciences
Research Interests: Chemical Immunomodulatory approaches to combat cancer, multivalent metastatic cell targeting oligomers, covalent re-engineering of immunological machinery and the cancer cell surface
Anthony Rullo
PhD
Associate Professor
Associate Member, Department of Biochemistry and Biomedical Sciences
Sam Schulman
M.D., FRCPCC
Professor
Director, Clinical Thromboembolism Program Hamilton Health Sciences, Hamilton General Hospital
Sam Schulman
M.D., FRCPCC
Professor
Director, Clinical Thromboembolism Program Hamilton Health Sciences, Hamilton General Hospital
Frederick Spencer
MD, FRCPC
Professor
Research Interests: Epidemiology of arterial and venous thrombotic diseases with a specific focus on utilization of evidence-based therapies.
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Irwin Walker
MBBS, FRACP
Professor, Division of Hematology & Thromboembolism
Joseph E. DesRoches Chair in Bone Marrow Transplantation
Irwin Walker
MBBS, FRACP
Professor, Division of Hematology & Thromboembolism
Joseph E. DesRoches Chair in Bone Marrow Transplantation
Ted Warkentin,
MD, FRCPC
Professor Emeritus
Ted Warkentin,
MD, FRCPC
Professor Emeritus
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Michelle Zeller
MD, FRCPC, MHPE, DRCPSC
Associate Professor
Michelle Zeller
MD, FRCPC, MHPE, DRCPSC
Associate Professor
Donald Arnold
MD, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
John G. Kelton Chair in Translational Research
Donald Arnold
MD, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
John G. Kelton Chair in Translational Research
Shannon Bates
MDCM, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Eli Lilly Canada/May Cohen Chair in Women's Health
Shannon Bates
MDCM, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Eli Lilly Canada/May Cohen Chair in Women's Health
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Jonathan Bramson
PhD
Vice-Dean, Research
Professor, Division of Hematology & Thromboembolism; John Bienenstock Chair in Molecular Medicine
Research Interests: Immunology, Oncology, Translational Research, Genetic Engineering, Immunoassays/Immune Monitoring, First-in-human clinical trials
Jonathan Bramson
PhD
Vice-Dean, Research
Professor, Division of Hematology & Thromboembolism; John Bienenstock Chair in Molecular Medicine
Research Interests: Immunology, Oncology, Translational Research, Genetic Engineering, Immunoassays/Immune Monitoring, First-in-human clinical trials
Mark Crowther
MD, MSc, FRCPC
Professor; Chair, Department of Medicine
Leo Pharma Chair in Thromboembolism Research; Clinical Epidemiology and Biostatistics, Pathology and Molecular Medicine associate member
Education and Professional Standing
MD, University of Western Ontario, 1990
FRCPC Internal Medicine, 1994
FRCPC Hematology, 1995
MSc Health Research Methodology, 1998
Fellow of the Royal Society of Canada (FRSC), 2017
Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter’s annual publication of The World’s Most Influential Scientific Minds).
[View Dr. Crowther’s citations on PubMed]
Research Interests: Exploring ways of improving the way that we use our current anticoagulant drugs, including exploring established and novel interventions to mitigate bleeding and anticoagulant drugs in high-risk patient populations; Developing systematic reviews of key questions in hematology and thrombosis and basing guidelines on those reviews.
Mark Crowther
MD, MSc, FRCPC
Professor; Chair, Department of Medicine
Leo Pharma Chair in Thromboembolism Research; Clinical Epidemiology and Biostatistics, Pathology and Molecular Medicine associate member
Education and Professional Standing
MD, University of Western Ontario, 1990
FRCPC Internal Medicine, 1994
FRCPC Hematology, 1995
MSc Health Research Methodology, 1998
Fellow of the Royal Society of Canada (FRSC), 2017
Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter’s annual publication of The World’s Most Influential Scientific Minds).
[View Dr. Crowther’s citations on PubMed]
Research Interests: Exploring ways of improving the way that we use our current anticoagulant drugs, including exploring established and novel interventions to mitigate bleeding and anticoagulant drugs in high-risk patient populations; Developing systematic reviews of key questions in hematology and thrombosis and basing guidelines on those reviews.
John Eikelboom
MBBS, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Research; Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research
Dr John Eikelboom is an associate professor in the Department of Medicine at McMaster University in Hamilton, Ontario . After earning his MBBS degree at the University of Western Australia Medical School, Australia, he completed training in Internal Medicine and Haematology at Royal Perth Hospital, Australia and trained in Epidemiology and Thrombosis Medicine at McMaster University . He holds a Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research. Dr. Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding. He has published more than 150 peer-reviewed papers. He is a member of the Editorial Board for Stroke and on the Advisory Board for the Journal of Thrombosis and Haemostasis.
Research Interests: Mechanisms and genetic determinants of antiplatelet drug resistance and improving its diagnosis and treatment.
John Eikelboom
MBBS, MSc, FRCPC
Professor, Division of Hematology & Thromboembolism
Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Research; Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research
Dr John Eikelboom is an associate professor in the Department of Medicine at McMaster University in Hamilton, Ontario . After earning his MBBS degree at the University of Western Australia Medical School, Australia, he completed training in Internal Medicine and Haematology at Royal Perth Hospital, Australia and trained in Epidemiology and Thrombosis Medicine at McMaster University . He holds a Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research. Dr. Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding. He has published more than 150 peer-reviewed papers. He is a member of the Editorial Board for Stroke and on the Advisory Board for the Journal of Thrombosis and Haemostasis.
Research Interests: Mechanisms and genetic determinants of antiplatelet drug resistance and improving its diagnosis and treatment.
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Jeffrey Ginsberg
MD, FRCPC
Professor Emeritus
Jeffrey Ginsberg
MD, FRCPC
Professor Emeritus
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Patricia Liaw
BSc, MSc, PhD
Professor, Division of Hematology & Thromboembolism
Jack Hirsh-Clive Kearon Chair in Thrombosis
Patricia Liaw
BSc, MSc, PhD
Professor, Division of Hematology & Thromboembolism
Jack Hirsh-Clive Kearon Chair in Thrombosis
Brian Lichty
PhD
Associate Professor
Research Interests: Host-virus interactions and viral therapeutics for cancer
Brian Lichty
PhD
Associate Professor
Research Interests: Host-virus interactions and viral therapeutics for cancer
Davide Matino
MD, MSc
Assistant Professor, Division of Hematology & Thromboembolism
Bayer Chair for Clinical Epidemiology Research in Bleeding Disorders
Davide Matino
MD, MSc
Assistant Professor, Division of Hematology & Thromboembolism
Bayer Chair for Clinical Epidemiology Research in Bleeding Disorders
Siraj Mithoowani
MD, FRCPC
Assistant Professor
Member, McMaster Education Research, Innovation & Theory (MERIT) Program
Siraj Mithoowani
MD, FRCPC
Assistant Professor
Member, McMaster Education Research, Innovation & Theory (MERIT) Program
Ishac Nazy
PhD
Associate Professor
Research interests are in the specific interactions between antibodies and their target antigens on platelets, leading to thrombocytopenia and/or thrombosis. Heparin induced thrombocytopenia and Immune thrombocytopenia (ITP) are great models for identifying key factors involved in the pathogenesis of the immune responses leading to low platelet counts. Our research focuses on the cellular and humoral immunity and the downstream effects on platelet physiology. We use our research to identify the pathology from patient samples and create in-vitro models that could explain our findings and further our understanding of the issues at hand.
Ishac Nazy
PhD
Associate Professor
Research interests are in the specific interactions between antibodies and their target antigens on platelets, leading to thrombocytopenia and/or thrombosis. Heparin induced thrombocytopenia and Immune thrombocytopenia (ITP) are great models for identifying key factors involved in the pathogenesis of the immune responses leading to low platelet counts. Our research focuses on the cellular and humoral immunity and the downstream effects on platelet physiology. We use our research to identify the pathology from patient samples and create in-vitro models that could explain our findings and further our understanding of the issues at hand.
Anthony Rullo
PhD
Associate Professor
Associate Member, Department of Biochemistry and Biomedical Sciences
Research Interests: Chemical Immunomodulatory approaches to combat cancer, multivalent metastatic cell targeting oligomers, covalent re-engineering of immunological machinery and the cancer cell surface
Anthony Rullo
PhD
Associate Professor
Associate Member, Department of Biochemistry and Biomedical Sciences
Research Interests: Chemical Immunomodulatory approaches to combat cancer, multivalent metastatic cell targeting oligomers, covalent re-engineering of immunological machinery and the cancer cell surface
Sam Schulman
M.D., FRCPCC
Professor
Director, Clinical Thromboembolism Program Hamilton Health Sciences, Hamilton General Hospital
Sam Schulman
M.D., FRCPCC
Professor
Director, Clinical Thromboembolism Program Hamilton Health Sciences, Hamilton General Hospital
Frederick Spencer
MD, FRCPC
Professor
Research Interests: Epidemiology of arterial and venous thrombotic diseases with a specific focus on utilization of evidence-based therapies.
Frederick Spencer
MD, FRCPC
Professor
Research Interests: Epidemiology of arterial and venous thrombotic diseases with a specific focus on utilization of evidence-based therapies.
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Irwin Walker
MBBS, FRACP
Professor, Division of Hematology & Thromboembolism
Joseph E. DesRoches Chair in Bone Marrow Transplantation
Irwin Walker
MBBS, FRACP
Professor, Division of Hematology & Thromboembolism
Joseph E. DesRoches Chair in Bone Marrow Transplantation
Ted Warkentin,
MD, FRCPC
Professor Emeritus
Ted Warkentin,
MD, FRCPC
Professor Emeritus
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.
Michelle Zeller
MD, FRCPC, MHPE, DRCPSC
Associate Professor
Michelle Zeller
MD, FRCPC, MHPE, DRCPSC
Associate Professor
Hematology & Thromboembolism – Part-Time & Affiliated Faculty
Information Box Group
Stephanie Carlin
MD
Assistant Clinical Professor
Stephanie Carlin
MD
Assistant Clinical Professor
Federico Germini
MD, FRCPC
Assistant Professor (Part-Time)
Federico Germini
MD, FRCPC
Assistant Professor (Part-Time)
Yi Ying (Regina) Li
MD
Assistant Clinical Professor (Adjunct)
Yi Ying (Regina) Li
MD
Assistant Clinical Professor (Adjunct)
Yang Liu
MD
Lecturer (Adjunct)
Yang Liu
MD
Lecturer (Adjunct)
Maria Fe C. Medina
PhD
Assistant Professor
Faculty
Research Interests: Manufacturing of adenoviral vectors for pre-clinical and clinical applications
Deborah Siegal
MD, FRCPC
Associate Professor (Part-Time)
Deborah Siegal
MD, FRCPC
Associate Professor (Part-Time)
Kartiga Thiyagarajah
MD, FRCPC
Assistant Clinical Professor (Adjunct)
Kartiga Thiyagarajah
MD, FRCPC
Assistant Clinical Professor (Adjunct)
Stephanie Carlin
MD
Assistant Clinical Professor
Stephanie Carlin
MD
Assistant Clinical Professor
Federico Germini
MD, FRCPC
Assistant Professor (Part-Time)
Federico Germini
MD, FRCPC
Assistant Professor (Part-Time)
Yi Ying (Regina) Li
MD
Assistant Clinical Professor (Adjunct)
Yi Ying (Regina) Li
MD
Assistant Clinical Professor (Adjunct)
Yang Liu
MD
Lecturer (Adjunct)
Yang Liu
MD
Lecturer (Adjunct)
Maria Fe C. Medina
PhD
Assistant Professor
Faculty
Research Interests: Manufacturing of adenoviral vectors for pre-clinical and clinical applications
Maria Fe C. Medina
PhD
Assistant Professor
Faculty
Research Interests: Manufacturing of adenoviral vectors for pre-clinical and clinical applications
Deborah Siegal
MD, FRCPC
Associate Professor (Part-Time)
Deborah Siegal
MD, FRCPC
Associate Professor (Part-Time)
Kartiga Thiyagarajah
MD, FRCPC
Assistant Clinical Professor (Adjunct)
Kartiga Thiyagarajah
MD, FRCPC
Assistant Clinical Professor (Adjunct)
Hematology & Thromboembolism – Leadership
Information Box Group
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.